Novartis Ag (NVS) Share-based Compensation (2019 - 2025)
Novartis Ag's (NVS) quarterly Share-based Compensation came in at -$424.0 million in Q1 2025, down 55.88% year-over-year from -$961.1 million in Q1 2024, and down 55.88% quarter-over-quarter from -$272.0 million in Q1 2024.
Powered by 
Analysis
Novartis Ag (NVS) Share-based Compensation (2019 - 2025) Analysis & Trends
Novartis Ag has disclosed Share-based Compensation across 3 years of filings, most recently posting -$424.0 million for Q1 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 641.98 Bn | 621.22 Bn | 17.26 Bn | -950.00 Mn |
| 2 | AbbVie | 446.60 Bn | 440.03 Bn | 12.70 Bn | 166.00 Mn |
| 3 | Merck | 357.75 Bn | 350.61 Bn | 12.21 Bn | 298.00 Mn |
| 4 | Novartis Ag | 267.43 Bn | 259.74 Bn | 11.24 Bn | - |
| 5 | Pfizer | 156.61 Bn | 144.91 Bn | 10.94 Bn | 249.00 Mn |
| 6 | Sanofi | 52.22 Bn | 44.84 Bn | 10.79 Bn | - |
| 7 | Revolution Medicines | 42.95 Bn | 42.95 Bn | - | 277.20 Mn |
| 8 | Incyte | 24.57 Bn | 20.04 Bn | 1.57 Bn | 67.26 Mn |
| 9 | United Therapeutics | 21.31 Bn | 18.65 Bn | 683.80 Mn | 19.00 Mn |
| 10 | Neurocrine Biosciences | 15.81 Bn | 15.42 Bn | 935.80 Mn | 65.00 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2025 | -424.00 Mn |
| Mar 31, 2024 | -272.00 Mn |
| Dec 31, 2019 | 454.00 Mn |